References
- Le Poole I C, Das P K, van den Wijngaard R MJGJ, et al. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993; 2: 145–53
- Cui J, Shen L Y, Wang G C. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991; 97: 410–16
- Le Poole I C, van den Wijngaard R MJGJ, Westerhof W, et al. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol 1993; 100: 816–22
- Antoniou C H, Katsambas A. Guidelines for the treatment of vitiligo. Drugs 1992; 43: 490–8
- Nordlund J J, Halder R M, Grimes P. Management of vitiligo. Dermatol Clin 1993; 11: 27–33
- Schallreuter K U, Wood J M, Lemke K R, et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995; 190: 223–9
- Biella U. Phenylalanin und UV in der Behandlung der Vitiligo. Akt Dermatol 1993; 19: 125–8
- Stierner U, Rosdahl I, Augustsson A, et al. UVB irradiation induces melanocyte increase in both exposed and shielded human skin. J Invest Dermatol 1989; 92: 561–4
- Köster W, Wiskemann A. Phototherapie mit UVB bei Vitiligo. Z Hautkr 1990; 65: 1022–9
- Baumer F E, Frisch W, Milbradt R, et al. Erhöhte Expression des OKM5-Antigens auf Blutmonozyten bei Vitiligo. Z Hautkr 1990; 65: 914–19
- Ortonne J P, Bose S K, Vitiligo. where do we stand?. Pigment Cell Res 1993; 6: 61–72
- Kao C H, Yu H S. Comparison of the effect of 8-methoxypsoralen (8-MOP) plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro. J Invest Dermatol 1992; 98: 734–40
- Song M S, Hann S K, Ahn P S, et al. Clinical study of vitiligo. Comparative study of type A and type B vitiligo. Ann Dermatol 1994; 6: 22–30
- Cui J, Arita Y, Bystryn J C. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993; 100: 812–15
- Shong Y K, Kim J A. Vitiligo in autoimmune thyroid disease. Thyroidol Clin Exp 1991; 3: 89–91
- Hsin S Y, Chao-Hsin K, Chia-Li Y. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with nonsegmental-type vitiligo. J Invest Dermatol 1993; 100: 823–8
- Gilhar A, Zelickson B, Ulman Y, et al. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995; 105: 683–6
- Gruner S, Zwirner A, Boonen H, et al. Einfluß einer Behandlung mit Salz des Toten Meeres (Tomesa-Therapie) auf epidermale Langerhanszellen - Eine klinische Studie. Z Hautkr 1990; 65: 1146–51
- Stüttgen G. Balneotherapie heute aus dermatologischer Sicht. TW Dermatologie 1992; 22: 206–15
- Ständer M. Mineralsalze zur Unterstützung der selektiven Ultraviolett-Phototherapie. Hautarzt 1991; 42: 402
- Blick U. Katamnestische Untersuchungen zur Behandlung der Vitiligo am Toten Meer. Präv Rehab 1994; 3: 105–8
- Dourmishev A L. Studies on the mechanism of vitiligo repigmentation after thalassotherapy. Thalassotherapie, S Chlebarov. Grabe-Verlag, Immenstadt 1991; 205–9
- Calanchini-Postizzi E, Frenk E. Long-term actinic damage in sun-exposed vitiligo and normally pigmented skin. Dermatologica 1987; 174: 266–71
- Schallreuter K U, Leving C, Berger J. Vitiligo and cutaneous melanoma. Dermatologica 1991; 183: 239–45